Vasculitis and the kidney

Current Opinion in Nephrology and Hypertension

Volumn 5, Issue 3, 1996, Pages 273-281

  Rees, Andrew J ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE ANTIBODY;

DISEASE CLASSIFICATION; GLOMERULONEPHRITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VASCULITIS;

ANIMALS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BIOLOGICAL MARKERS; HUMANS; INCIDENCE; RENAL CIRCULATION; VASCULITIS;

EID: 0029992139     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199605000-00014     Document Type: Review

References (123)

1. Gross WL, Schmitt WH, Csernok E: ANCA and associated diseases: immunodiagnostic and pathogenetic aspects. Clin Exp Immun 1993, 91:1-12.
2. Van der Woude FJ, Van Es LA: Pathogenesis of angiitis. In Oxford Textbook of Clinical Nephrology Ch. 4.5.1. Edited by Cameron JS, Davison AM, Grunfeld JP, Kerr DNS, Ritz E. Oxford: Oxford University Press; 1992:583-594.
3. Davson J, Ball J, Platt R: The kidney in periarteritis nodosa. Q J Med 1948, 17:175-202.
4. The American College of Rheumatology: 1990 criteria for classification of vasculitis. Arthr Rheum 1990, 33:1065-1144.
5. Baranger TAR, Audrain MAP, Testa A, Besnier D, Guillevin L, Esnault VLM: Anti-neutrophil cytoplasm antibodies in patients with ACR criteria for polyarteritis nodosa: help for systemic vasculitis classification. Autoimmun 1995, 20:33-37.
6. Guillevin L, Lhote F: Distinguishing polyarteritis nodosa from microscopic polyangiitis and implications for treatment. Curr Opin Rheumatol 1995, 7:20-24.
7. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kellenberg CG. et al.: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthr Rheum 1994, 37:187-192.
8. Angangco R, Thiru S, Esnault VL, Short AK, Lockwood CM, Oliveira DB: Does truly 'idiopathic' crescentic glomerulonephritis exist? Nephrol Dial Transplant 1994, 9:630-636.
9. Sinico RA, Radice A, Pozzi C, Ferrario F, Arrigo G: Diagnostic significance and antigen specificity of antineutrophil cytoplasmic antibodies in renal diseases. A prospective multicentre study. Italian Group of Renal Immunopathology. Nephrol Dial Transplant 1994, 9:505-510.
10. Saxena R, Bygren P, Arvastson B, Wieslander J: Circulating autoantibodies as serological markers in the differential diagnosis of pulmonary renal syndrome. J Intern Med 1995, 238:143-152.
11. Davies DJ, Moran JE, Niall JF, Ryan GB: Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? BMJ 1982, 285:606.
12. ••] are truly authoritative reviews of ANCA and vasculitis.
13. ••].
14. Zhao MH, Jones SJ, Lockwood CM: Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis. Clin Exp Immun 1995, 99:49-56.
15. Kain R, Matsui K, Exner M, Binder S, Schaffner G, Sommer EM, Kerjaschki D: A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotising and crescentic giomerulonephritis: the lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells. J Exp Med 1995, 181:585-597.
16. Abott F, Jones S, Lockwood CM, Rees AJ: Autoantibodies to glomerular antigens in patients with Wegener's granulomatosis. Nephrol Dial Transplant 1989, 4:1-8.
17. Davenport A, Lock RJ, Wallington TB, Feest TG: Clinical significance of anti-neutrophil cytoplasm antibodies detected by a standardised indirect immunofluorescence assay. Q J Med 1994, 87:291-299.
18. Rao JK, Allen NB, Feussner JR, Weinberger M: A prospective study of antineutrophil cytoplasmic antibody (c-ANCA) and clinical criteria in diagnosing Wegener's granulomatosis. Lancet 1995, 346:926-931.
19. Baslund B, Segelmark M, Wiik A, Szpirt W, Petersen J, Wieslander J: Screening for anti-neutrophil cytoplasmic antibodies (ANCA): is indirect immunofluorescence the method of choice? Clin Exp Immun 1995, 99:486-492.
20. Haapala AM, Soppi E, Hyoty H: Circulating myeloperoxidase may cause false negative findings in the analysis of myeloperoxidase antibodies in systemic vasculitis. Scand J Immunol 1994, 40:317-322.
21. Andrassy K, Koderisch J, Waldherr R, Rufer M: Diagnostic significance of anticytoplasmic antibodies (ACPA/ANCA) in detection of Wegener's granulomatosis and other forms of vasculitis. Nephron 1988, 49:257-258.
22. Andrews M, Edmunds M, Campbell A, Walls J, Feehally J: Systemic vasculitis in the 1980s: is there an increasing Incidence of Wegener's granulomatosis and microscopic polyarteritis? J R Coll Phys Lond 1990, 24:284-288.
23. Watts RA, Carruthers DM, Scott DGI: Epidemiology of systemic vasculitis: changing incidence or definition? Semin Arthr Rheum 1995, 25:28-34. The most complete study of the prevelance of vasculitis.
24. Garrett PJ, Dewhurst AG, Morgan LS, Mason JC, Dathan JR: Renal disease associated with circulating antineutrophil antibody. Q J Med 1992, 85:731-749.
25. Geerlings W, Tufveson G, Ehrich JHH, Jones EHP, Landose P, Loirate C, Mallick NP, Margreiter R, Raine AE, Salmela K, et al.: Report on management of renal failure in Europe, XXIII. Nephrol Dial Transplant 1995, 9:6-25.
26. Rottem M, Cotch MF, Fauci AS, Hoffman GS: Familial vasculitis: report of 2 families. J Rheumatol 1994, 21:561-563.
27. Heuze-Claudot L, Leroy B, Chevallier A, Noel L, Cau D, Daniel P, Beauvois P: A familial ANCA-associated pulmonary-renal syndrome [Abstract]. Clin Exp Immun 1993, 93(suppl):40.
28. Esnault VLM, Testa A, Audrain M, Roge C, Hamidou M, Barrier JH, Sesboue R, Martin JP, Lesavre P: Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int 1993, 43:1329-1332.
29. O'Donoghue DJ, Guickian M, Blundell G, Winney RJ: Alpha-1-proteinase inhibitor and pulmonary haemorrhage in systemic vasculitis. In: ANCA-associated vasculitides: immunological and clinical aspects. Edited by Gross WL. New York: Plenum Press; 1993:331-335.
30. Lhotta K, Vogel W, Meisl T, Buxbaum M, Neyer U, Sandholzer C, Konig P: Alpha 1-antitrypsin in patients with anti-neutrophil cytoplasmic antibody-positive vasculitis. Clin Sci 1994, 87:693-695.
31. Savige JA, Chang L, Cook L, Burdon J, Daskalakis M, Doery J: Alpha 1-antitrypsin deficiency and anti-proteinase 3 antibodies in anti-neutrophil cytoplasmic antibody (ANCA)-associated systematic vasculitis. Clin Exp Immunol 1995, 100:194-197.
32. Elzouki AN, Segelmark M, Wieslander J, Enksson S: Strong link between the alpha 1-antitrypsin PiZ allele and Wegender's granulomatosis. J Intern Med 1994, 236:543-548.
33. 1 anti-trypsin deficiency and susceptability to ANCA-associated vasculitis.
34. Muller GA, Gebhardt M, Kompf J, Baldwin WM: Association between rapidly progressive glomerulonephritis and the properdin factor BfF and different HLA-D region products. Kidney Int 1984, 25:115-118.
35. Spencer SJW, Burns A, Gaskin G, Pusey CD, Rees AJ: HLA class II specificities in vasculitis with antibodies to neutrophil cytoplasmic antigens. Kidney Int 1992, 41:1059-1063.
36. Hagen EC, Stegeman CA, D'Amaro J, Shrender GMT, Lems SPM, Cohen Tervaert JW, DeJong GMTh, Hene RJ, Kellenberg CGM, Daha MR: Decreased frequency of HLA B-DR6 in Wegener's granulomatosis. Kidney Int 1995, 48:801-805.
37. Zhang L, Jayne DR, Zhao MH, Lockwood CM, Oliveira DB: Distribution of MHC class II alleles in primary systematic vasculitis. Kidney Int 1995, 47:294-298.
38. Finn JE, Zhang L, Agrawal S, Jayne DRW, Oliveira DB, Mathieson PW: Molecular analysis of C3 allotypes in patients with systemic vasculitis. Nephrol Dial Transplant 1994, 9:1564-1567.
39. Devogelaer JP, Pirson Y, Vandenbroucke JM, Cosyns JP, Brichard S, Nagant de Deuxchaisney C: D-penicillamine induced crescentic glomerulonephritis: report and review of the literature. J Rheumatol 1987, 14:1030-1041.
40. Jones BF, Major GA: Crescentic glomerulonephritis in a patient taking penicillamine associated with anti-neutrophil cytoplasmic antibodies. Clin Nephrol 1992, 38:293-295.
41. Gaskin G, Thompson EM, Pusey CD: Goodpasture-like syndrome associated with anti-myeloperoxidase antibodies following penicillamine treatment. Nephrol Dial Transplant 1995, 10:1925-1928.
42. Mason PD, Lockwood CM: Rapidly progressive nephritis in patients taking hydralazine. Clin Lab Immunol 1986, 20:151-153.
43. Nassberger L, Sjoholm AG, Bygren P, Thysell H: Circulating anti-neutrophil cytoplasm antibodies in patients with rapidly progressive glomerulonephritis and extracapillary proliferation. J Intern Med 1989, 225:191-196.
44. Gregorini G, Ferioli A, Donato F, Tira P, Morassi L: Association between silica exposure and necrotising crescentic glomerulonephritis with P-ANCA and anti-MPO antibodies: a hospital-based case control study. In ANCA-associated vasculitides: clinical and immunological aspects. New York: Plenum Press; 1993, 435-440.
45. Nuyts GD, Van Vlem E, De Vos A, Daelemans RA, Rorive G, Elseviers MM, Schurgers M, Segaert M, Haese PCD, De Broe ME: Wegener granulomatosis is associated to exposure to silicon compounds: a case-control study. Nephrol Dial Transplant 1995, 10:1162-1165.
46. Savage COS, Winearls CG, Evans DJ, Rees AJ, Lockwood CM: Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med 1985, 56:467-483.
47. Leruez-Ville M, Lauge A, Morinet M, Guillevin L, Deny P: Polyarteritis nodosa and parvovirus B19. Lancet 1994, 344:263-264.
48. Falk RJ, Jennette JC: Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotising and crescentic glomerulonephritis. N Engl J Med 1988, 318:1651-1657.
49. •] are important studies documenting sequential ANCA titres in follow-up studies in patients with systemic vasculitis.
50. •]
51. Harper JH, Lockwood CM, Cooke A: Anti-neutrophil cytoplasmic antibodies in MRL-lpr/lpr mice. Clin Exp Immun 1993, 93(suppl 1):22.
52. Kettritz R, Yang JJ, Kinjo K, Jennette JC, Falk RJ. Animal models in ANCA-vasculitis. Clin Exp Immun 1995, 101(suppl 1):12-15.
53. Mathieson PW, Qasim FJ, Esnault VLM, Oliveira DBJ: Animal models of systemic vasculitis. J Autoimmun 1993, 6:251-264.
54. Johnson RJ: The mystery of the antineutrophil cytoplasmic antibodies. Am J Kidney Dis 1995, 26:57-61.
55. Van de Wiel BA, Dolman KM, Van der Meer-Gerritsen CH, Hack CE, Von dem Borne KGEKr, Goldschmeding R: Interference of Wegener's granulomatosis autoantibodies with neutrophll proteinase 3 activity. Clin Exp Immun 1992, 90:409-414.
56. 1-antitrypsin complexation to disease activity in Wegener's granulomatosis. Clin Exp Immun 1993, 93:405-410.
57. Daouk GH, Palsson R, Arnaout MA: Inhibition of proteinase 3 by ANCA and its correlation with disease activity in Wegener's granulomatosis. Kidney Int 1995, 47:1528-1536.
58. Dolman KM, Jager A, Sonnenberg A, von dem Borne AEG: Proteolysis of classic anti-neutrophil cytoplasmic autoantibodies (C-ANCA) by neutrophil proteinase 3. Clin Exp Immun 1995, 101:8-12.
59. Bendtzen K, Svenson M, Jonsson V, Hippe E: Autoantibodies to cytokines - friends or foes? Immun Today 1990, 11:167-169.
60. Falk RJ, Terell RS, Charles LA, Jennette JC: Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 1990, 87:4115-4119.
61. Calafat J, Goldschmeding R, Ringeling PL, Janssen H, van der Schoot CE: In situ localisation of double-labeling immunoelectron microscopy of anti-neutrophil cytoplasmic autoantibodies in neutrophil and monocytes. Blood 1990, 75:242-250.
62. Csernok E, Ludemann E, Gross WL, Bainton DF: Ultrastructural localisation of proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in Wegener's granulomatosis. Am J Pathol 1990, 137:1113-1120.
63. Csernok E, Ernst M, Schmitt W, Bainton DF, Gross WL: Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immun 1994, 95:244-250.
64. Porges AJ, Redecha PB, Kimberley WT, Csernok E, Gross WL, Kimberly RP: Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via FcγRIIa. J Immunol 1994, 153:1271-1280. Demonstration of the importance of FCγRII in ANCA-associated activation of neutrophils.
65. Mulder AH, Heeringa P, Brouwer E, Limburg PC, Kallenberg CG: Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): a Fc gamma RII-dependent process. Clin Exp Immun 1994, 98:270-278.
66. Mulder AH, Stegeman CA, Kallenberg CG: Activation of granulocytes by anti-neutrophil cytopasmic antibodies (ANCA) in Wegener's granulomatosis: a predominant role for the IgG3 subclass of ANCA. Clin Exp Immunol 1995, 101:227-232. This paper describes a possible pathogenic role tor IgG3 as opposed to other subclasses of ANCA in nephritis.
67. Csernok E, Ernst M, Schmitt W, Bainton DF, Gross WL: Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immun 1994, 95:244-250.
68. Mayet WJ, Meyer zum Buschenfeld KH: Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelium. Clin Exp Immun 1993, 94:440-446; Blood 1993, 82:1221-1229.
69. Mayet WJ, Meyer zum Buschenfeld KH: Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelium. Clin Exp Immun 1993, 94:440-446; Blood 1993, 82:1221-1229.
70. Savage COS, Pottinger BE, Gaskin G, Pusey CD, Pearson JD: Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity towards cultured endothelial cells. Am J Pathol 1992, 141:335-342.
71. Ewert BH, Jennette JC, Falk RJ: Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int 1992, 41:375-383.
72. Mayet WJ, Csernok E, Szymkowiak C, Gross WL, Meyer ZUM, Buschenfeld KD: Human endothelial cells express proteinase 3, the target antigen in Wegener's granulomatosis. Blood 83:1221-1229.
73. King WJ, Adu D, Daha MR, Brooks CJ, Radford DJ, Pall AA, Savage COS: Endothelial cells and renal epithelial cells do not express the Wegener's autoantigen, proteinase 3. Clin Exp Immun 1995, 102:98-105.
74. Brouwer E, Huitema MG, Klok PA, Cohen Tervaert JW, Weening JJ, Kallenberg CGM: Anti-myeloperoxidase associated proliferative glomerulonephritis: an animal model. J Exp Med 1993, 177:905-914.
75. Brouwer E, Klok PA, Huitema MG, Weening JJ, Kallenberg CG: Renal ischemia/reperfusion injury contributes to renal damage in experimental anti-myeloperoxidase-associated proliferative glomerulonephritis. Kidney Int 1995, 47:1121-1129. Careful studies confirming the relationship between the intensity of inflammation and persistence of detectable immunoglobulin in MPO-induced glomerulonephritis.
76. Brouwer E, Klok PA, Weening JJ, Kallenberg CGM: Development of anti-myeloperoxidase associated glomerulonephritis in Brown Norway and Lewis rats: effects of strain differences in immune responsiveness [Abstract]. J Am Soc Nephrol 1994, 5:776.
77. Yang JJ, Jennette JC, Falk RJ: Immune complex glomerulonephritis is induced in rats immunized with heterologous myeloperoxidase. Clin Exp Immun 1994, 97:466-473.
78. Germuth FG Jr, Valdes AJ, Taylor JJ, Wise O'L, Rodriguez E. Fatal immune complex glomerulonephritis without deposits. Johns Hopkins Med J 1975, 136:189-192.
79. Braverman IM, Yen A: Demonstration of immune complexes in spontaneous and histamine-induced and normal skin in patients with leukocytoclastic vasculitis. J Invest Dermatol 1975, 64:105-112.
80. Oite T, Shimizu F, Kagami S, Morioka T: Hapten-specific cellular immune response producing glomerular injury. Clin Exp Immunol 1989, 76:463-468.
81. Rennke HG, Klein PS, Sandstrom DJ, Mendrick DL: Cell-mediated immune injury in the kidney: acute nephritis induced in the rat by azobenzenearsonate. Kidney Int 1994, 45:1044-1056.
82. Brouwer E, Stegeman CA, Huitema MG, Limburg PC, Kallenberg CG: T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG). Clin Exp Immunol 1994, 98:448-453.
83. Ballieux BE, van der Burg SH, Hagen EC, van der Woude FJ, Melief CJ, Daha MR: Cell-mediated autoimmunity in patients with Wegener's granulomatosis (WG). Clin Exp Immunol 1995, 100:186-193.
84. Griffith ME, Coulthart A, Pusey CD: T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis. Clin Exp Immun 1996, 103:253-258.
85. Mathieson PW, Lockwood CM, Oliveira DBG. T and B cell responses to netrophil cytoplasmic antigens in systemic vasculitis. Clin Exp Immun 1992, 63:135-141.
86. Simpson IJ, Skinner MA, Geursen A, Peake JS, Abott WG, Fraser JD, Lockwood CM, Tan PL: Peripheral blood T lymphocytes in systemic vasculitis: increased T cell receptor V beta 2 gene usage in microscopic polyarteritis. Clin Exp Immunol 1995, 101:220-226.
87. Giscombe R, Grunewald J, Nityanand S, Lefvert AK: T cell receptor (TCR) V gene usage in patients with systemic necrotizing vasculitis. Clin Exp Immunol 1995, 101:213-219.
88. + T-cell subsets in Wegener's granulomatosis. Rheum Int 1995, 14:213-219.
89. Mrowka CH, Csernok E, Gross WL, Feucht HE, Bechtel U, Thoenes GH: Distribution of the granulocyte serine proteinases proteinase 3 and elastase in human glomerulonephritis. Am J Kidney Dis 1995, 25: 253-261.
90. Kobayashi K, Shibata T, Sugisaki T: Aggravation of rat nephrotoxic serum nephritis by anti-myeloperoxidase antibodies. Kidney Int 1995 47:454-463.
91. Gross WL, Rasmussen N: Treatment of Wegener's granulomatosis: the view from two non-nephrologists. Nephrol Dial Transplant 1994, 9:1219-1222. An authoratitive review of the current treatment of Wegener's granulomatosis.
92. Falk RJ, Hogan S, Carey TS, Jennette JC: Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med 1990, 113:656-663.
93. Haubitz M, Frei U, Rother U, Brunkhorst R, Koch KM: Cyclophosphamide pulse therapy in Wegener's granulomatosis. Nephrol Dial Transplant 1991, 6:531-535.
94. Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Franci AS: Treatment of Wegener's granulomatosis with intermittent high dose intravenous cyclophosphamide. Am J Med 1990, 89:403-410.
95. Reinhold Keller E, Kekow J, Schnabel A, Schmitt WH, Hellor M, Beigel A, Duncker G, Gross WL: Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthr Rheum 1994, 37:919-924.
96. Genereau T, Lortholary O, Leclerq P, Grenet D, Tubery M, Sicard D, Caubarrere I, Guillevin L: Treatment of systemic vasculitis with cyclophosphamide and steroids: daily oral low-dose cyclophosphamide administration after failure of a pulse intravenous high-dose regimen in four patients. Br J Rheumatol 1994, 33:959-962.
97. Gordon M, Luqmani RA, Adu D, Greaves I, Richards N, Michael J, Emery P, Howie AJ, Bacon PA: Relapses with patients with a systemic vasculitis. Q J Med 1993, 86:779-789.
98. Haubitz M, Brunkhorst R, Schellong S, Gobel U, Schurek HJ, Koch KM: A prospective randomised study comparing daily oral versus monthly i.v. cyclophosphamide applications in patients with ANCA-associated vasculitis and renal involvement (preliminary results) [Abstract]. Clin Exp Immun 1995, 101(suppl 1):43.
99. Guillevin L, Lhote F, Jarrousse B, Cohen P, Jacquot C: Treatment of severe Wegener's granulomatosis (WG): a prospective trial comparing prednisone (CS), pulse cyclophosphamide (CY) versus CS and oral CY [Abstract]. Clin Exp Immun 1995, 101(suppl 1):43.
100. Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM: Plasma exchange in focal necrotising glomerulonephritis without anti-GBM antibodies. Kidney Int 1991, 40:757-763.
101. Cole E, Cattran D, Magil A, Greenwood C, Churchill D, Sutton D, Clark W, Morrin P, Posen G, Bernstein K et al.: A prospective randomised trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. Am J Kidney Dis 1992, 20:261-269.
102. Bolton WK, Sturgill BC: Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis. Am J Nephrol 1989, 9:368-375.
103. McLelland P, Williams PS, Stevens ME, Bone JM: [Letter]. Nephrol Dial Transplant 4:917.
104. Andrassy K, Erb A, Koderisch J, Waldherr R, Ritz E: Wegener's granulomatosis with renal involvement: patient survival and correlations between initial renal function, renal histology, therapy and renal outcome. Clin Nephrol 1991, 35:139-147.
105. Levy JB, Winearls CG: Rapidly progressive glomerulonephritis: what should be first-line therapy? Nephron 1994, 67:402-407.
106. Rasmussen N, Jayne DRW, Abramowicz D, Andrassy K, Bacon PA, Cohen Tervaert JW, Dadonlene J, Feighery C, van Es LA, Ferrario F et al.: European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. Clin Exp Immun 1995, 101(suppl 1):29-34.
107. Hoffman GS, Leavitt RY, Kerr GS, Fauci AS: The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arth Rheum 1992, 35:1322-1329.
108. Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS: An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthr Rheum 1995, 38:608-613. A good description of the largest series of patients with Wegener's granulomatosis treated with methotrexate.
109. Pall AA, Varagunam M, Adu D, Smith N, Richards NT, Taylor CM, Michael J: Anti-idiotypic activity against anti-myeloperoxidase antibodies in pooled human immunoglobulin. Clin Exp Immun 1994, 95:257-262.
110. Jayne DRW, Davies MJ, Fox CJV, Black CM, Lockwood CM: Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991, 337:1137-1140.
111. Richter C, Schnabel A, Csernok E, DeGroot K, Reinhold-Keller E, Gross WL: Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 1995, 101:2-7. A study describing the largest experience of the use of intravenous immunoglobulin in systemic vasculitis.
112. DeRemee RA: The treatment of Wegener's granulomatosis with trimethoprim/sulphamethoxazole: illusion or vision? Arthr Rheum 1988, 31:1068-1072.
113. Reinhold-Keller E, De Groot K, Rudert H, Nolle B, Heller M, Gross WL: Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. Q J Med 1996, 89:15-23. This study reviews current experience with co-trimoxazole for maintaining remission in Wegener's granulomatosis.
114. Stegemann CA, Cohen Tervaert JW, Manson WL, Kallenberg CGM: Chronic nasal carriage of staphylococcus aureus in Wegener's granulomatosis: identification of a subgroup more prone to relapses. Ann Intern Med 1994, 120:12-17.
115. Lawyer C, Henkle J Kakir H: Nasal carriage of staphylococcal infection in Wegener's granulomatosis. Ann Intern Med 1994, 121:74-75.
116. Mathieson PW, Cobbold SP, Hale G, Clark MR, Oliveira DB, Lockwood CM: Monoclonal antibody therapy in systemic vasculitis. N Engl J Med 1990, 323:250-254.
117. Lockwood CM, Thiru S, Isaacs JD, Hale G: Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993, 341:1620-1622.
118. Hagen EC, de Keizen RJW, Androssy K, van Boven WP, Bruijn JA, van Es LA, van der Woude FJ: Compassionate treatment of Wegener's granulomatosis with rabbit anti-thymocyte globulin. Clin Nephrol 1995, 43:351-359. Both this and [116] describe the successful use of anti-T cell antibodies to treat patients with fulminant systemic vasculitis.
119. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS: Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992, 116:488-498.
120. Geffriaud Ricourard C, Noel LH, Chauveau D, Houhou S, Grunfeld JP, Lesavre P: Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients. Clin Nephrol 1993, 39:125-136.
121. John S, Neumayer HH, Weber M: Serum circulating ICAM-1 levels are not useful to indicate active vasculitis or early renal allograft rejection. Clin Nephrol 1994, 42:369-375.
122. Mrowka C, Sieberth HG: Detection of circulating adhesion molecules ICAM-1, VCAM-1 and E-selectin in Wegener's granulomatosis, systemic lupus erythematosus and chronic renal failure. Clin Nephrol 1995, 43:288-296.
123. Pall AA, Adu D, Drayson M, Taylor CM, Richards NT, Michael J: Circulating soluble adhesion molecules in systemic vasculitis. Nephrol Dial Transplant 1994, 9:770-774.